Ars.els-cdn.com



Supplemental Table 1. Baseline and operative profiles of grafts before and after propensity-score matching. Before matching After matchingVariableSequentialN=946Individual N=1,366P valueSMD(%)SequentialN=819IndividualN=819SMD(%)Age, yrs64.6±8.863.4±9.30.00213.164.1±8.864.2±9.10.6Female, n (%)232 (24.5)318 (23.3)0.522.9199 (24.3)187 (22.8)3.5Body mass index, kg/m224.4±2.824.6±2.80.274.624.5±2.724.5±2.860.8Creatinine, mg/dL1.26±1.661.08±0.980.00112.91.25 (1.68)1.10 (1.08)10.6Estimated glomerular filtration rate, mL/min/1.73m275.8±21.777.9±19.40.01610.176.4±21.476.8±19.32.0Hemoglobin, g/dL12.8±1.813.0±1.810.00312.512.9±1.712.9±1.72.1Diabetes mellitus, n (%)449 (47.5)568 (41.6)0.00611.9365 (44.6)373 (45.5)2.0Hypertension, n (%)548 (57.9)792 (58.0)0.990.1471 (57.5)475 (58.0)1.0Current smoker, n (%)130 (13.7)197 (14.4)0.692.0113 (13.8)112 (13.7)0.4Former smoker, n (%)364 (38.5)520 (38.1)0.880.8319 (38.9)328 (40.0)2.2Recent myocardial infarction (<60 days), n (%)141 (14.9)149 (10.9)0.00511.998 (12.0)106 (12.9)3.0Previous percutaneous coronary intervention, n (%)148 (15.6)209 (15.3)0.871.0131 (16.0)127 (15.5)1.3Cerebrovascular accident, n (%)84 (8.9)118 (8.6)0.900.970 (8.5)69 (8.4)0.4Peripheral vascular disease, n (%)60 (6.3)70 (5.1)0.2455.247 (5.7)38 (4.6)5.0Dialysis, n (%)37 (3.9)26 (1.9)0.00512.030 (3.7)19 (2.3)7.9Atrial fibrillation, n (%)20 (2.1)29 (2.1)0.990.119 (2.3)13 (1.6)5.3Left ventricular ejection fraction, %55.0±11.555.8±11.40.136.455.4±11.255.5±11.40.4Left ventricular end-systolic dimension, mm34.2±8.233.9±8.60.383.733.9±7.933.7±8.62.7Left ventricular end-diastolic dimension, mm50.8±6.451.0±6.70.463.150.7±6.250.7±6.60.6Significant mitral regurgitation (Gr≥3), n (%)32 (3.4)30 (2.2)0.117.223 (2.8)14 (1.7)7.4Significant tricuspid regurgitation (Gr≥3), n (%)6 (0.6)7 (0.5)0.921.64 (0.5)1 (0.1)6.6Off-pump coronary arterial bypass grafting, n (%)688 (72.7)898 (65.7)<0.00115.2591 (72.2)606 (74.0)4.1Aspirin used within 48hrs after CABG, n (%)929 (98.2)1334 (97.7)0.453.8802 (97.9)804 (98.2)1.8Clopidogrel Bisulfate used within 48hrs after CABG, n (%)990 (95.5)1323 (96.9)0.136.8794 (96.9)797 (97.3)2.2Surgical years<0.00130.1 Early period (2005-2009)393 (41.5)771 (56.4)381 (46.5)389 (47.5) Late period (2010-2016)553 (58.5)595 (43.6)438 (53.5)430 (52.5)SMD, standardized mean difference; CABG, coronary arterial bypass grafting; SVG, saphenous vein graft.Data are mean (± SD) or numbers (percentages). The standardized differences are reported as percentages; a difference of less than 10.0% indicates a relatively small imbalance.Supplemental Table 2. Adjusted risks of sequential saphenous vein grafts for graft failure as compared with sub-grouped individual grafts. Hazard ratio95% CIP valueversus Individual SVG bypassing LCX0.990.49-2.010.98versus Individual SVG bypassing RCA0.550.35-0.86<0.001versus Free radial artery bypassing LCX0.670.33-1.310.28SVG, saphenous vein graft; LCX, left circumflex artery; RCA, right coronary artery. Supplemental Figure 1. Unadjusted rates of graft failure in sequential saphenous vein grafts bypassing both LCX and RCA territory (A) versus individual vein grafts bypassing LCX territory, (B) versus individual vein grafts bypassing RCA territory, (C) versus individual vein grafts bypassing PDA/PL, and (D) versus individual vein grafts bypassing distal main RCA (dRCA) .LCX, left circumflex artery; PDA, posterior descending artery; PL, posterolateral branch; RCA, right coronary artery; RA, radial artery.Supplemental Figure 2. Unadjusted rates of graft failure in sequential saphenous vein grafts bypassing both LCX and RCA territory versus free radial artery grafts bypassing LCX.LCX, left circumflex artery; RCA, right coronary artery; RA, radial artery. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download